



Article

Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals

McCourt, Fiona, O'Neill, Brenda, Logan, Ian, Abbott, Janice, Plant, Barry, McCrum-Gardner, Evie, McKeown, Stephanie, Stuart Elborn, J and Bradley, Judy M

Available at <http://clock.uclan.ac.uk/11403/>

McCourt, Fiona, O'Neill, Brenda, Logan, Ian, Abbott, Janice ORCID: 0000-0001-9851-1236, Plant, Barry, McCrum-Gardner, Evie, McKeown, Stephanie, Stuart Elborn, J and Bradley, Judy M (2015) Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals. Journal of Cystic Fibrosis, 14 (1). pp. 90-96. ISSN 15691993

It is advisable to refer to the publisher's version if you intend to cite from the work.
<http://dx.doi.org/10.1016/j.jcf.2014.06.007>

For more information about UCLan's research in this area go to <http://www.uclan.ac.uk/researchgroups/> and search for <name of research Group>.

For information about Research generally at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the [policies](#) page.

Title

INDICATORS OF PULMONARY EXACERBATION IN CYSTIC FIBROSIS: A DELPHI SURVEY OF PATIENTS AND HEALTH PROFESSIONALS

Running title

INDICATORS OF EXACERBATION IN CF: A DELPHI SURVEY

Authors

Fiona McCourt ^{a,*}, Brenda O'Neill ^{a,*}, Ian Logan ^a, Janice Abbott ^b, Barry Plant ^c, Evie McCrum-Gardner ^a, Stephanie McKeown ^a, J. Stuart Elborn ^{d,^} and Judy M. Bradley ^{a, e, ^}

***joint first authors; ^joint senior authors**

Authors affiliations

^a *Centre for Health and Rehabilitation Technologies, Institute of Nursing and Health Research, University of Ulster, Northern Ireland, United Kingdom, BT37 OQB*

^b *School of Psychology, University of Central Lancashire, Preston, England, United Kingdom, PR1 2HE*

^c *Cork Adult CF Centre, Cork University Hospital, University College Cork, Wilton, Cork, Ireland*

^d *Centre for Infection and Immunity, Queen's University, Belfast, Northern Ireland, United Kingdom, BT9 7BL*

^e *Department of Respiratory Medicine, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom BT9 7AB*

Corresponding Author

Dr Fiona McCourt

Northern Ireland Clinical Trials Unit (NICTU), 1st Floor Elliott Dynes, The Royal Group of Hospitals, Grosvenor Road, Belfast, BT12 6BA

Tel +44 2890 63 1903

Email fiona.mccourt@nictu.hscni.net

<http://dx.doi.org/10.1016/j.jcf.2014.06.007>

Abstract

Background: There is uncertainty about the most important indicators of pulmonary exacerbations in CF. *Methods:* Two parallel Delphi surveys in 13 CF centres (UK and Ireland). Delphi 1: 31 adults with CF, \geq one exacerbation over 12 months. Delphi 2: 38 CF health professionals. Rounds 1 and 2 participants rated their level of agreement with statements relating to indicators of exacerbation; Round 3 participants rated the importance of statements which were subsequently placed in rank order. *Results:* Objective measurements were of higher importance to health professionals. Feelings of increased debility were rated most important by adults with CF. *Conclusions:* There were clear differences in perspectives between the two groups as to the most important indicators of an exacerbation. This highlights that CF health professionals should take more cognisance of specific signs and symptoms reported by adults with CF, especially since these may be a precursor to an exacerbation.

Keywords: Pulmonary exacerbation; Delphi Technique; Cystic fibrosis

1. Introduction

Pulmonary exacerbations (PEX) in cystic fibrosis (CF) are associated with disease progression, increased morbidity, mortality, and substantial healthcare costs [1-4]. PEX are experienced by a large proportion of patients with CF. The most recent annual information from the CF Registry of Ireland reported 451 paediatric admissions and 680 adult admissions for a PEX treated with intravenous antibiotics, using data that was available for 881 of registered patients [5]. The CF Registry of the UK reported 3732 paediatric lung infections and 5062 adult lung infections using data that was available for 8794 registered patients [6]. Minimising PEXs is critical for the long term health of adults with CF since patients who have more than two PEX per year have a significantly reduced three year survival compared to those who have one or none [4]. PEXs are associated with a more rapid decline in FEV₁, which results in a further decline in overall wellbeing [7, 8]. Health related quality of life (HRQoL) worsens during PEX and more severe exacerbations have a greater negative impact on HRQoL [1, 8]. Most people with CF die of respiratory failure which has typically been induced by a PEX [9, 10, 11].

PEXs are also frequently used as an end point in clinical trials and recommended by European Medicines Agency (EMA) and Food and Drug Administration (FDA) as primary efficacy end points [2, 12, 13, 14]. However, neither agency mandates any definition of a PEX. Consequently definitions used in clinical trials are multiple and are inconsistent with each other [15]. In addition, they often show inconsistencies with criteria routinely used by CF health professionals [16-18].

Previously it was suggested that the Delphi technique is an appropriate methodology to identify which criteria should be included in a definition of a PEX in CF [17]. This technique uses a series of repeated surveys to gain consensus on a given issue [19-22].

This method reduces peer pressure and encourages unbiased responses, as participants remain anonymous to the core members of the research team and to other participants [19, 21-23]. The Delphi technique is a practical, efficient, inexpensive and widely used consensus research method in health care research [24, 25].

The aim of this study was to identify the important indicators of an exacerbation determined by a group of adults with CF and a group of CF health professionals.

2. Methods

2.1 Design and recruitment

Two parallel Delphi surveys were used to investigate agreement among a group of adults with CF and CF health professionals regarding the important indicators of an exacerbation.

This was a multicentre study across the UK and Ireland. Twenty-seven CF centres were approached to take part aiming to recruit two to three adults with CF and two to three CF health professionals per centre. Participants were identified by a designated key health professional at each CF centre who was responsible for ensuring all participants met the inclusion criteria for their participant group. The inclusion criteria for adults with CF were: confirmed diagnosis of CF, over 18 years, FEV₁ less than or equal to 80% predicted, experienced at least one exacerbation requiring IV antibiotics in the previous 12 months and computer literate with internet access available for the duration of the study. The inclusion criteria for CF Health Professionals were: CF health professionals working in adult CF centres in the UK/Ireland, currently involved in assessing if CF patients are having an exacerbation and deciding a treatment plan and computer literate with internet access available for the duration of the study.

The stages of this Delphi survey are summarised in Figure 1. Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland. Research governance was sought at participating sites. Data collection took place over a seven month period (Sept 2010-April 2011). In each round non responders were followed up and sent

weekly reminders to complete the survey.

2.2 Delphi Round 0: Statement Generation

The aim of Round 0 was to generate a list of statements for Round 1 of the Delphi survey. The first step in developing the Delphi survey for this study was to conduct a systematic literature search and extract criteria used to identify an exacerbation. This search identified 218 criteria from 86 articles. However, there were many similarities in the terminology used, consequently criteria that were similar in meaning were grouped together to form one category. The list of 218 criteria was condensed to form 31 themes, which were then agreed by the research team.

The themes were built on further through the results of patient interviews with 47 adults with CF to identify their perception of the indicators of an exacerbation and a review of CF specific quality of life instruments [16, 26, 27]. While these questionnaires are assessing quality of life, they contain signs, symptoms and feelings that are related to people with CF and are used in clinical trials and in clinical practice to help identify the health status of patients which were not already covered by the themes identified.

The agreed themes were used to formulate statements for “Round 1” of the Delphi survey. Finally, health professionals at the Belfast CF centre independently reviewed the statements. A few minor changes were made. One issue related to haemoptysis that can have a range of severity levels. It was agreed that it should be represented as two separate statements: ‘Sputum streaked with blood’ and ‘Frank haemoptysis’ (referred to as ‘Coughing up blood’ in the adults with CF survey). Although it was recognized that haemoptysis is not a particularly common feature of exacerbations in CF, clearly frank bleeding is of concern. The research team therefore agreed that inclusion of two statements were sufficient when considering this potential sign.

The statements were then piloted with several adults with CF to ensure clarity of the wording. The research team recognise there is some overlap between some of the statements used in the Delphi survey, however, this was partly as a result of the feedback from the adults with CF. For example, they considered there was a distinction between the statements, “Feeling more short of breath than usual” and “Trouble breathing” and advised that they should remain as distinct statements. The adults with CF also provided their views on different response formats recommended for use in Delphi methodology in order to inform the preferred response format for this survey and to finalise the survey [22]. Two surveys with statements (n=48) focussing on indicators of PEX were compiled, one for adults with CF and one for CF health professionals. The only difference was in the use of lay terminology in the patient survey e.g. instead of haemoptysis “Sputum streaked with blood in sputum” was used.

2.3 Delphi Round 1

Two Delphi surveys were administered simultaneously using the web based survey tool ‘Survey Monkey’ [28]. Both participant groups were given the same survey in Round 1, the only difference being that, where appropriate, the terminology was provided in lay terms for the adults with CF. Participants were asked to rate their level of agreement with each statement using a five point Likert scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree) with an additional option of “don’t know”. For example, participants were asked to indicate their agreement with the statement that “Feeling more tired than usual, is an important indicator of pulmonary exacerbation”. There was also an open question where participants were able to add additional criteria/items to avoid missing

any important issues.

2.4 Delphi Round 2

In Round 2 statements from Round 1 that did not reach consensus (defined as 75% agreement), along with five additional statements identified from the open question were presented to both groups. In Round 2, the adults with CF survey contained 32 statements and the CF health professional survey contained 30 statements. Participants were also provided with a summary of the results from Round 1 for their participant group; this included their individual original response, the group response, and a summary chart showing the responses to that particular statement. Participants were asked to reconsider the statement again, taking into account the feedback of results from Round 1, and to re-rate their level of agreement with each statement. They were advised that they did not have to change their response if they did not wish to. There were five additional statements developed from the open question in Round 1 which were also presented as new statements using the original format from Round 1.

2.5 Delphi Round 3

In Round 3 participants were presented with statements that had reached 75% agreement in Round 1 or 2. Both surveys contained 35 statements (Adults with CF survey: 31 statements along with four additional statements to rate that had only reached consensus in the health professionals survey; CF health professionals survey: 30 statements along with five additional statements to rate that had only reached consensus in the adults with CF survey). Participants were asked to rate the level of importance on a scale of one to 10, where one represented the lowest level of importance and ten represented the highest level of importance.

2.6 Data analysis

The data generated from each round was analysed with SPSS 17.0 using descriptive statistics. The data from each participant group was analysed separately. The researcher summarising the data from all rounds was blinded to the study participant's identity. In order to identify which statements had reached consensus in Round 1 or Round 2 the percentage agreement and median response were calculated. In Delphi surveys the level of consensus is determined prior to initiating data collection, and this can vary depending on the topic being investigated. A consensus level of 75% was selected following guidance from the literature; this meant including responses where a person had indicated that they 'Strongly Agree' or 'Agree' [21]. For Round 3 results were analysed by applying a rating average and then placing criteria in a ranked order of importance, in order to identify factors of importance within each group and to facilitate comparison between the groups. Further analysis was conducted in Round 3 to identify if the differences for individual statements between the groups were statistically significant, using the independent T-Test for statements with normally distributed data and the Mann Whitney U test was used for data which was not normally distributed.

3. Results

The CF centres that participated in this study were identified through the CF Trust website (www.cftrust.org.uk) and the CF Association of Ireland website (www.cfireland.ie). The centres were all specialist CF centres providing care for adults with CF. All 27 centres identified were invited to participate in the study and data was obtained from 13 (48%). Of the 14 centres that did not participate, seven declined due to a *variety of reasons* including commitments to other studies or staffing restraints, five did not respond, and two agreed

initially but due to difficulties with their local research governance approval they were unable to take part.

In Round 1, 31 adults with CF with moderate to severe disease completed the survey. The participants ranged from age 23 to 52 years. All participants confirmed that they had experienced at least 1 exacerbation in the previous year (defined by their centre) and were treated with IV antibiotics. The number of exacerbations reported by the adults with CF were 1-3 n=17; 4-6 n=11; >6 n=3. A lung function (FEV₁%predicted) of less than 40% was reported by 11 participants and 8 participants reported a lung function of 40-60%. In Rounds 2 and 3 the surveys were completed by 28 and 27 participants respectively.

All 38 CF health professionals who registered completed all survey rounds. Their professions are as follows: nurse n=13, physiotherapist n=6, dietician n=1, doctor n=18. By the end of Round 2, 31 statements from adults with CF, and 30 statements from CF health professionals, had reached consensus (Figure 1). In Round 3 there were clear differences between adults with CF and CF health professionals as to the important indicators of an exacerbation. Tables 1 and 2 show the mean scores, standard deviation and rating order for all the statements (adults with CF and health professionals) from Round 3. Indicators from the adults with CF that were rated of higher importance were commonly rated lower by CF health professionals; for example, "An increase in symptoms at night" was rated higher by adults with CF (rank order 5) and lower by CF health professionals (rank order 29). Indicators from CF health professionals that were rated high were commonly rated lower by patients with CF; for example "Haemoptysis (blood streaked sputum)" was rated higher by CF health professionals (rank order 13) and lower by adults with CF (rank order 33).

It is difficult to select a cut off point however; few statements were rated high by both groups. For example the top ten indicators from the adults with CF, six of these were not ranked in the top 10 by CF health professionals. In the top 10 indicators from the CF health professionals, six of these were not ranked in the top 10 by adults with CF. The four statements in the top 10 where there was agreement were "A large decrease in lung function (Greater than 10% FEV₁)", "Feeling more short of breath than usual", "Producing more sputum than usual" and "More coughing than usual". Although FEV₁ is an objective indicator it is perhaps not surprising that it appeared as the top item on the adults with CF list, since there is a big emphasis on this measurement in the clinic. Examination of the standard deviations for each of the indicators showed that there was reasonably good agreement for individual criteria, although there was a trend to a reduced level of consensus in the less highly rated criteria. Following analysis via the independent T-Test or Mann Whitney U, there were 15 statements in Tables 1 & 2 which showed a statistically significantly different rating with a p-value <0.05. While it is interesting to note results which were significantly different this was, of necessity, a semi-quantitative study. While a certain degree of importance can be placed on the statistical significance, the research team felt more importance should be placed on the clinical relevance which is detailed through the hierarchy of average rating scores for each group.

4. Discussion

This study has used a series of surveys, including an initial systematic analysis of the literature, to clarify what are the key criteria for identifying a PEX in CF. It has demonstrated that adults with CF and CF health professionals generally identify a different hierarchy of important indicators of PEX. In general, the important indicators identified by the adults with CF were more subjective than those identified by the health professionals, who preferred more objective clinical measurements (Tables 1 and 2). The importance of physiological measurements, such as oxygen saturation, to CF clinicians has recently been reported in a study using clinical vignettes to identify exacerbation criteria [18]. However, often the relationship between changes in physiological measurements and changes in symptoms and function in people with respiratory conditions are weak, and this may help to explain why patients have different criteria than health professionals.

It is not surprising that the two groups identified different hierarchies of importance for the signs and symptoms since they have access to different information; the patients experience symptoms, whereas the health professionals observe or measure them, or rely on patient reporting whichever symptoms they think are relevant, possibly in response to specific questioning by the clinician. A more defined series of questions and/or tests might help to improve information gathering. The timing of when indicators of an exacerbation occur could also be relevant, as symptoms may be apparent to patients which later trigger the health professionals to evaluate with objective investigations. This highlights that CF health professionals should consider the signs and symptoms described by an adult with CF; this is especially pertinent when the patient indicates that a specific symptom is often a likely precursor to an exacerbation in their condition.

Currently available criteria-based definitions only capture some of the indicators that were rated important in our study [15]. For example, indicators such as “Feeling the need to do more airways clearance than usual” which were considered important by adults with CF in our study are not in current criteria. Also indicators in our study such as “Increased inflammatory markers” considered important by health professionals are not in the current criteria [15]. Other indicators of PEX such as the four that Adults with CF and CF health professionals agreed were important (Tables 1 and 2) are captured in current definitions. These variations represent the complexity involved in developing an agreed definition and resulting clinical tool(s) or research tool. However, attempting to define an exacerbation in CF continues to be relevant because the presence/absence of an exacerbation is recognised by EMA as an important end point [14].

A single set of criteria may not be the most useful in defining an exacerbation in CF. It may be more accurate to identify an individual set of signs and symptoms of a PEX for each patient; the extent of the deviation from their “usual signs and symptoms” could then be used to identify an exacerbation. This could be valuable to enable patients to share their management with their health professional, and perhaps incorporate an action plan relating to monitoring usual symptoms and recognising the onset of an exacerbation. It could help clinical teams to standardise the criteria used for admission to hospital with an exacerbation and with decisions around commencing oral or IV antibiotics, or more intensive therapy. If the criteria were useful in establishing the severity of the exacerbation this could help with decisions around treatment delivered at home versus hospital. It could also have a research utility in assessing response of specific therapies in limiting the severity of exacerbations by bench marking efficacy against clearly identified personalised criteria for each individual patient. This is generally what CF clinicians do informally as part of clinical reasoning, and it would be helpful if this was formalised into a tool that could be used by patients at home and in clinical trials.

Further research is required to build on the findings of this study. It is notable that the signs and symptoms that prompt adults with CF to seek medical attention are often different from those considered most important by the health professionals. Therefore, a dialogue between clinicians and patients should be encouraged to help individuals identify which signs and symptoms are critical for them in identifying the onset of a PEX. The aim would be to promote earlier engagement with their CF centre which could result in earlier intervention and triage of treatment options. The results of this study could also be used to explore if the criteria selected by CF health professionals provide scope for helping to determine treatment plans. A clinical tool may be an appropriate way forward. For example, the Chronic Respiratory Disease Questionnaire (CRDQ) enables patients to identify up to 5 activities which induce breathlessness; in the same way a clinical tool for defining PEX could consider 5 (or more) criteria which individual patients select as important in defining their exacerbation [29]. A new tool could also incorporate objective indicators that health professionals consider important. For example, the Asthma Control Questionnaire incorporates patient’s views on whether their asthma is under control as well an objective measurement of Peak Respiratory Flow Rate [30]. Any new tool should consider that different indicators of a PEX may be associated with different degrees of disease severity and also different severity of exacerbation [16].

Despite the high response rate with 94% of participants completing all three rounds of the Delphi, a limitation of this study is the small sample size. However, we included a large spread of centres across the British Isles giving confidence that we obtained a representative range of experience from CF centres of different sizes and localities. In Delphi studies it is proposed that the consensus level be defined in advance of acquiring the data so that the researchers cannot influence the outcome of the survey [22]. We chose the 75% consensus level through reference to previously published Delphi studies but the choice of a specific consensus level is an aspect of Delphi methodology that remains contentious [22]. The validity of our study was optimised by providing explicit participant inclusion criteria, pilot testing, setting a predetermined consensus level, and monitoring the number of rounds [20-23].

5. Conclusions

This study used a Delphi consensus method to ascertain important indicators of PEX from the perspectives of adults with CF and CF health professionals. There were clear differences in perspectives between the two groups in relation to the important indicators of an exacerbation in CF.

Contributor Statement Page

All authors attest to the following roles in the preparation of this manuscript:

- 1) Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data – McCourt, O'Neill, Logan, Abbott, Plant, McCrum-Gardner, McKeown, Elborn, Bradley.
- 2) Drafting the article or revising it critically for important intellectual content – McCourt, O'Neill, Logan, Abbott, Plant, McCrum-Gardner, McKeown, Elborn, Bradley.
- 3) Final approval of the version to be published – McCourt, O'Neill, Logan, Abbott, Plant, McCrum-Gardner, McKeown, Elborn, Bradley.

Acknowledgements

This study was part of a PhD project funded by the Health and Social Services Research and Development Office, Northern Ireland. The research team would like to thank everyone who contributed to this study including the cosponsors of the study: the University of Ulster and the Belfast Health and Social Care Trust, and the CF centres which participated i.e.

Belfast Health and Social Care Trust

Cork University Hospital

Kings College Hospital NHS Trust

Leeds Teaching Hospital NHS Trust

Nottingham University Hospitals NHS Trust

Oxford Radcliffe Hospitals NHS Trust

Plymouth Hospitals NHS Trust

Southampton University Hospitals NHS Trust

University Hospital Bristol

University Hospital of North Staffordshire

University Hospital of South Manchester

NHS Greater Glasgow and Clyde

NHS Lothian

Reference List

- [1] Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. *Eur Respir J* 2013;41(3):571-77.
- [2] Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. *Eur Respir J* 2011;38(5):1071-80.
- [3] Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. *J Pediatr* 2006;148(2):259-64.
- [4] de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. *Thorax* 2011;66(8):680-85.
- [5] Cystic Fibrosis Registry of Ireland. 2012 Annual Report. [Online] Available from: http://www.cfri.ie/docs/annual_reports/CFRI2012.pdf [Accessed 06 Feb 2014].
- [6] UK Cystic Fibrosis Registry (2013) UK Cystic Fibrosis Registry Review 2012 [Online] Available from: https://www.cysticfibrosis.org.uk/media/181982/Registry_review_A4_v6.pdf [Accessed 06 Feb 2014].
- [7] Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall B C. Predictive 5-year survivorship model of cystic fibrosis. *Am J Epidemiol* 2001;153(4):345-52.
- [8] Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. *Chest* 2002;121(1):64-72.
- [9] Elpern EH, Cheatham J. Inpatient care of the adult with an exacerbation of cystic fibrosis. *AACN Clin Issues* 2001;12(2):293-304.
- [10] Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel P, Dhainaut J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. *Am J Respir Crit Care* 2005;171(2):158-64.
- [11] Paranjape SM, Barnes LA, Carson KA, von Bergc K, Loosenc H, Mogayzel PJ. Exercise improves lung function and habitual activity in children with cystic fibrosis. *J Cyst Fibros* 2012;11:18–23.
- [12] Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty C, Marks G, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *New Eng J Med* 2006;354(3):229-40.
- [13] Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims. [Online] Available from: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf> [Accessed 03 Feb 2013].
- [14] European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. [Online] Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500017055.pdf [Accessed 04 March 2013].
- [15] Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. *Thorax* 2007;62:360-67.
- [16] Abbott J, Holt L, Morton AM, MacDougall L, Posgon M, Milne G, et al. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. *J Cyst Fibros* 2009;8:356-59.
- [17] Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. *Pediatr Pulmonol* 2001;31:436-42.
- [18] Krainack NC, Gothard MD, Fallenta, LM, McBride, JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. *Pediatr Pulmonol* 2011;46(9):870-81.
- [19] Beretta R. A critical review of the Delphi technique. *Nurse Res* 1996; 3(4):79-89.
- [20] Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs* 2000;32(4):1008-15.

- [21] Keeney S, Hasson F, McKenna H. Consulting the oracle: ten lessons from using the Delphi technique in nursing research. *J Adv Nurs* 2006;53(2):205-12.
- [22] Keeney S, Hassan F, McKenna H. *The Delphi Technique in Nursing and Health Research*. 1st ed. Oxford :Wiley-Blackwell; 2011.
- [23] Bowles, N. The Delphi technique. *Nurs Stand* 1999;13(45):32-36.
- [24] Jones J, Hunter D. Qualitative research: Consensus methods for medical and health services research. *Brit Med J* 1995;311:376-80.
- [25] Ahern NR. Using the Internet to conduct research. *Nurs Res* 2005;13(2),55.
- [26] Gee L, Abbott J, Conway S, Etherington C, Webb AK. Development and validation of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. *Thorax* 2000;55(11):946-54.
- [27] Quittner AL, Sweeny S, Watrous M, Munzenberger P, Bearss K, Gibson Nitza A, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. *J Pediatr Psychol* 2000 Sep;25(6):403-14.
- [28] Survey Monkey, The simple way to create surveys [Homepage of Survey Monkey], [Online] Available from: <https://www.surveymonkey.com/> [Accessed 27 Sept 2012].
- [29] Guyatt GH, Berman LB, Townsend M, Pughley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. *Thorax* 1987;42:773-78.
- [30] Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. *Eur Respir J* 1999;14:902-7.

Fig. 1. Summary of the stages of the Delphi surveys.
Key. Health professionals: HPs, cystic fibrosis: CF.




Table 1.

Indicators of an exacerbation from a Delphi survey in adults with CF: mean scores, standard deviation and rank order of each statement.

Statement	Mean score	Std. deviation	Rank order
A large decrease in lung function (greater than 10% FEV₁)	9.33	0.784	1^a
Feeling more short of breath than usual	8.52	1.087	2^a
Trouble breathing	8.52	1.805	2
Feeling the need to do more airway clearance than usual	8.37	1.115	4
An increase in symptoms at night	8.22	1.450	5
Producing more sputum	8.19	1.388	6^a
Finding it harder than normal to do your usual exercise	7.96	1.581	7
Finding it harder than normal to do your usual activities	7.93	1.838	8
Feeling more exhausted than usual	7.85	1.703	9
More coughing than usual	7.85	1.610	9^a
A change in the colour of your sputum	7.78	1.601	11
More wheezing or chest tightness	7.7	1.815	12
Feeling more fatigue than usual	7.59	1.760	13
Generally feeling unwell	7.59	1.716	13
Breathing at a faster rate than usual	7.48	1.805	15
Thicker sputum than usual	7.44	2.082	16
Less energy than usual	7.41	1.600	17
Feeling more tired than usual	7.37	1.779	18
Having to use more inhaled medications (i.e. inhalers, mucolytics) than usual	7.33	2.287	19
Knowing you have an increase in the infection markers in your blood (for example CRP, white cell count)	7.33	2.201	19
Knowing that your oxygen levels are low	7.33	2.130	19
More chest pain than usual	7.33	2.434	19
Coughing up blood	7.15	2.231	23
Knowing that you have a decrease in your oxygen saturation	7.15	2.013	23

(measured with a finger probe)

Increased time spent resting	7.11	1.672	25
Sputum that is harder to cough up	7.11	1.888	25
Fever or increased temperature	7.07	2.183	27
A change in the taste of your sputum	7.04	2.047	28
Loss of appetite	6.93	1.859	29
Knowing that you have new bacteria in your sputum	6.81	2.095	30
Generally looking unwell	6.81	2.113	30
Knowing that you have new additional breath sounds when your chest is examined	6.78	1.888	32
Sputum streaked with blood	6.7	1.728	33
Weight loss	6.59	1.947	34
Knowing that you have new changes on chest x-ray	6.56	1.888	35

Bold = the top 10 statements ranked.

Note: Scores with the same average rating were given the same joint ranked position.

a - Also ranked in the top 10 by CF HPs.

Table 2.

Indicators of an exacerbation from a Delphi survey in CF health professionals: mean scores, standard deviation and rank order of each statement.

Statement	Mean score	Std. deviation	Rank order
Increased sputum	8.84	1.027	1^a
A large decrease in lung function (greater than 10% FEV₁)	8.84	1.263	1^a
More shortness of breath than usual	8.32	1.141	3^a
Increased inflammatory markers (for example CRP and white cell count)	7.92	1.124	4
Fever or increased temperature	7.89	1.269	5
Increased respiratory rate at rest	7.82	1.557	6
Decreased oxygen saturation	7.79	1.510	7
Hypoxia/hypoxemia	7.76	1.807	8
Change in the colour of sputum	7.61	1.636	9
New changes on chest X-ray	7.47	1.767	10
Increased coughing	7.47	1.466	10^a
Trouble breathing	7.42	1.500	12
Haemoptysis (blood streaked sputum)	7.34	1.760	13
Decreased exercise tolerance	7.32	1.416	14
Feeling the need to do more airway clearance than usual	7.21	1.379	15
New added breath sounds on auscultation	7.08	1.807	16
Frank haemoptysis (fresh blood)	7.08	2.306	16
Increased thickness (viscosity) of sputum	7.05	1.559	18
Having to use more inhaled medications (i.e. inhalers, mucolytics) than usual	7.03	1.197	19
Difficulty performing usual activities	6.74	1.655	20
Feeling more tired than usual	6.71	1.575	21
Increased wheeze or chest tightness	6.66	1.419	22
Difficulty clearing sputum	6.66	1.475	22
Generally feeling unwell	6.63	1.601	24

Feeling more fatigue	6.58	1.571	25
Weight loss	6.5	1.928	26
Feeling more exhausted than usual	6.47	1.640	27
Decreased appetite	6.29	1.541	28
Increased symptoms at night	6.26	1.884	29
Lack of energy	6.24	1.532	30
Chest pain	6.11	1.721	31
Change in the taste of sputum	5.92	1.978	32
Generally looking unwell	5.89	1.813	33
Increased time spent resting	5.76	1.667	34
New bacteria in sputum	5.5	2.153	35

Bold = the top 10 statements ranked.

Note: Scores with the same average rating were given the same joint ranked position.

a - Also ranked in the top 10 by adults with CF.